Tresiba Cost in Massachusetts 2026: Cash Price, Medicaid, and Insurance Guide

What Is the Actual Cash Price of Tresiba in Massachusetts in 2026?

The manufacturer list price for Tresiba is approximately $510 per month in 2026, but almost no Massachusetts patient pays that figure. GoodRx, NeedyMeds, and direct manufacturer discount cards consistently bring the out-of-pocket cost to around $35 per month at major Massachusetts retail chains including CVS, Walgreens, and Walmart Pharmacy. Prices vary by dose (100 units/mL vs. 200 units/mL FlexTouch pen) and by the specific pharmacy's contract pricing.

Insulin pricing in the United States has long been a subject of policy scrutiny. The FDA's ongoing biosimilar approval program has introduced additional competitive pressure on basal insulin pricing since 2021. Insulin Lispro Biosimilar FDA approval set a precedent for list-price compression that has carried into the degludec market, though no FDA-approved biosimilar of insulin degludec was available as of early 2026. [1]

Massachusetts patients should call at least three pharmacies before filling, because the same GoodRx coupon can produce a $12 to $20 spread across zip codes. The 90-day supply price at Costco Pharmacy (no membership required for prescriptions) often undercuts 30-day pricing at traditional chains by 15 to 25 percent. Patients using the Novo Nordisk savings card (discussed below) may pay as little as $99 per month with commercial insurance, and certain qualifying uninsured patients may access insulin through the Novo Nordisk Patient Assistance Program at no cost. [2]

Does MassHealth (Massachusetts Medicaid) Cover Tresiba?

MassHealth covers Tresiba for both type 1 and type 2 diabetes, but the coverage requires prior authorization (PA). Without an approved PA on file, the claim will reject at the pharmacy counter. The PA process typically asks the prescriber to document that a formulary-preferred basal insulin (most commonly insulin glargine U-100 or U-300) has been tried and either failed to achieve glycemic targets or caused clinically significant adverse effects such as nocturnal hypoglycemia.

The MassHealth Pharmacy Program publishes its current preferred drug list (PDL) at mass.gov/masshealth. Insulin degludec sits in a non-preferred tier, which is why PA is required. [3] A 2022 analysis published in Diabetes Care found that formulary restrictions on basal insulins increased emergency department visits by approximately 8 percent among Medicaid beneficiaries who were switched off their established regimen, underscoring the clinical importance of PA approvals when a patient is already stable on degludec. [4]

Prescribers submitting a PA for MassHealth should include: the patient's most recent HbA1c, documentation of at least one trial of a preferred basal insulin, and a clinical rationale (for example, hypoglycemia frequency or flexible dosing need). MassHealth typically renders PA decisions within 72 hours for standard requests and within 24 hours for urgent requests. Denials can be appealed; the MassHealth Fair Hearing process has overturned formulary denials when clinical documentation was thorough.

Patients enrolled in a MassHealth Managed Care Entity (MCE) such as Tufts Health Together, BMC HealthNet, or Wellcare should confirm coverage directly with their plan, because MCE formularies may differ from the standard MassHealth PDL.

What Does the Clinical Evidence Say About Tresiba?

Understanding why a prescriber would pursue PA for Tresiba, rather than accepting a formulary substitute, starts with the clinical data. Insulin degludec is a basal insulin with an ultra-long half-life of approximately 25 hours and a duration of action exceeding 42 hours, producing a flatter, more stable pharmacokinetic profile than insulin glargine U-100. [5]

The DEVOTE trial (N=7,637) compared insulin degludec with insulin glargine U-100 in patients with type 2 diabetes at high cardiovascular risk. Published in the New England Journal of Medicine in 2017, DEVOTE demonstrated that degludec was non-inferior to glargine for the composite of major adverse cardiovascular events (MACE), with a hazard ratio of 0.91 (95% CI 0.78 to 1.06, P<0.001 for non-inferiority). [6] Severe hypoglycemia rates were significantly lower with degludec: 4.9 percent of patients on degludec experienced at least one severe hypoglycemic episode versus 6.6 percent on glargine (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). [6]

The FDA-approved prescribing information for Tresiba notes that the flexible dosing schedule, allowing dose timing to vary by up to 8 hours from day to day, distinguishes degludec from other basal insulins. [7] This flexibility has particular clinical relevance for shift workers, patients with irregular meal schedules, and individuals managing type 1 diabetes who require predictable basal coverage without strict injection timing.

The BEGIN Basal-Bolus Type 1 trial (N=629) showed that insulin degludec achieved non-inferior HbA1c reduction compared to glargine at 52 weeks (estimated treatment difference: 0.01%, 95% CI -0.14 to 0.16), with a 25 percent lower rate of nocturnal confirmed hypoglycemia (P<0.001). [8] These hypoglycemia data form the backbone of most successful PA arguments for MassHealth.

The American Diabetes Association's 2024 Standards of Care in Diabetes state: "Insulin degludec may be preferred over insulin glargine U-300 or U-100 for patients with type 1 or type 2 diabetes who experience recurrent nocturnal hypoglycemia or who require flexible dosing." [9] That language directly supports the PA clinical narrative for MassHealth.

Is Compounded Insulin Degludec Legal in Massachusetts?

Compounded insulin degludec is legal in Massachusetts when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. The FDA's 503A framework, established under the Drug Quality and Security Act of 2013, permits licensed pharmacists to compound drugs for individual patients when a commercially available product does not meet the patient's clinical needs. [10]

Massachusetts pharmacies must hold an active 503A license from the Massachusetts Board of Registration in Pharmacy (BORP) to compound insulin degludec. The BORP enforces USP Chapter 797 sterile compounding standards, which govern beyond-use dating, sterility testing, and cleanroom requirements for injectable preparations. [11] Patients and prescribers can verify a pharmacy's 503A status through the BORP license lookup at mass.gov/dph.

The cost differential is substantial. Where a licensed 503A pharmacy does offer compounded insulin degludec, pricing may approach $0 out of pocket for uninsured patients accessing charitable or state assistance programs, compared to the $510 list price for the brand product. More typically, compounded degludec at a Massachusetts 503A pharmacy costs between $40 and $120 per month, depending on concentration and volume. Prescribers writing for compounded insulin degludec must specify the exact concentration (typically 100 units/mL or 200 units/mL), base vehicle, sterility standards, and beyond-use date on the prescription.

One important legal boundary: 503B outsourcing facilities, which can compound without patient-specific prescriptions, are not permitted to compound drugs that are essentially copies of commercially available FDA-approved products. Because brand Tresiba is commercially available, 503B facilities generally cannot compound insulin degludec at scale. The 503A route requires a patient-specific Rx and is the legally clear path in Massachusetts. [10]

How Does the Novo Nordisk Savings Card Work in Massachusetts?

The Novo Nordisk My$99Insulin program and the Tresiba Savings Card are the two main manufacturer assistance programs available to Massachusetts residents. Both programs have specific eligibility gates.

The My$99Insulin program caps the monthly cost at $99 for any Novo Nordisk insulin, including Tresiba, for patients who are commercially insured (not covered by Medicaid, Medicare, or any federal or state government program). The program does not require income documentation and is processed at the pharmacy counter using a savings card printed or downloaded from novonordisk-us.com. [2]

For uninsured patients, the Novo Nordisk Patient Assistance Program (PAP) provides Tresiba at no cost to individuals with household income at or below 400 percent of the federal poverty level who do not have insurance covering outpatient prescriptions. [2] Massachusetts residents can apply at novonordisk-us.com/pap or through a prescriber's office. Application processing typically takes 2 to 4 weeks; a 30-day bridge supply can sometimes be obtained while the application is pending.

Medicare Part D beneficiaries in Massachusetts saw insulin cost-sharing capped at $35 per month per the Inflation Reduction Act provision effective January 2023, which applies to all Part D-covered insulins including Tresiba on applicable plan formularies. [12] The Centers for Medicare and Medicaid Services confirmed this cap in CMS guidance published in 2023. [12] Medicare Advantage plans must follow the same $35 cap for covered insulins.

The Novo Nordisk savings card cannot be combined with the My$99Insulin program. Patients should choose the program that produces the lower out-of-pocket cost based on their specific plan's negotiated pricing.

Which Massachusetts Insurance Plans Cover Tresiba?

Coverage for Tresiba across Massachusetts commercial plans is inconsistent. Most large employers offering Blue Cross Blue Shield of Massachusetts, Tufts Health Plan, Harvard Pilgrim Health Care, and Aetna coverage in Massachusetts place insulin degludec on a non-preferred specialty or non-preferred brand tier, which means PA is typically required and cost-sharing is higher than for preferred insulins.

A 2023 survey by the American Diabetes Association found that among commercial plans nationally, only 38 percent covered basal insulin analogs without prior authorization, while 62 percent required either PA or step therapy. [13] Massachusetts mirrors that national pattern. Step therapy protocols at Massachusetts commercial insurers typically require a 30 to 90 day trial of a preferred basal insulin (glargine) before approving degludec.

Exceptions exist. Some employer-sponsored self-insured plans (which are governed by ERISA, not state insurance mandates) have open formularies that cover Tresiba at a standard brand copay without PA. Patients on self-insured plans should check their Summary of Benefits and Coverage (SBC) document, which is legally required to disclose formulary tier placement and PA requirements.

Massachusetts state employee plans through the Group Insurance Commission (GIC) use formularies administered by CVS Caremark. As of 2025, GIC formularies listed insulin degludec as non-preferred with PA required, but exceptions for established patients on degludec were routinely approved with documentation of HbA1c stability and hypoglycemia history. Prescribers can submit GIC PA requests electronically through CVS Caremark's provider portal.

The Massachusetts insulin law (MGL Chapter 175, Section 47BB) requires all state-regulated health plans to cover insulin without prior authorization during a 30-day emergency supply period, which can provide a bridge while a formal PA is processed. [14] That 30-day emergency provision does not replace the PA requirement for ongoing coverage, but it prevents a patient from running out of insulin while paperwork is pending.

Can You Get a Tresiba Prescription via Telehealth in Massachusetts?

Telehealth prescribing of Tresiba is permitted in Massachusetts. State law allows licensed Massachusetts prescribers to issue Schedule V and non-scheduled prescription drugs, including insulin, via audio-video telehealth encounters without a prior in-person visit, provided the prescriber conducts a clinically appropriate evaluation. [15]

Massachusetts also recognizes prescriptions issued via telehealth for patients who established care in person and are continuing an existing insulin regimen. For new patients initiating basal insulin for the first time, most endocrinologists and primary care providers will conduct at least one structured telehealth visit that includes a review of blood glucose logs, HbA1c, and injection site assessment before prescribing.

HealthRX clinicians in Massachusetts can initiate a Tresiba prescription or assist with a PA submission during a telehealth encounter. Patients should have their most recent HbA1c result (within 3 months), a list of current medications, and insurance card information available for the visit.

The Massachusetts Board of Registration in Medicine confirms that prescribing via telehealth for established patients with diabetes does not require in-person follow-up at any fixed interval, though annual in-person metabolic review is generally consistent with the ADA's Standards of Care recommendation for comprehensive diabetes evaluation. [9] [15]

How to Pay the Least for Tresiba in Massachusetts: A Step-by-Step Decision Path

The following decision path reflects clinical and administrative practice at Massachusetts-based endocrinology practices. Start at step 1 and stop at the step that resolves your situation.

Step 1. Check your insurance formulary. Log in to your insurer's member portal and search for "insulin degludec" or "Tresiba." Note the tier, PA requirements, and estimated cost-sharing. If your plan covers it at a tolerable copay, use your insurance and skip to step 6.

Step 2. If PA is required, ask your prescriber to submit it. Provide your HbA1c, a list of prior insulins tried, and any documented hypoglycemia events. Most PAs are resolved within 72 hours. [3]

Step 3. If you are commercially insured and the PA is denied or pending, apply for the My$99Insulin card. Download it at novonordisk-us.com. It works immediately at the pharmacy counter for most commercial plans.

Step 4. If you are on Medicare Part D, confirm the $35/month insulin cap applies to your plan's coverage of Tresiba. Call your Part D plan's member services line; the cap is mandatory but requires the drug to be on the plan's formulary. [12]

Step 5. If you are uninsured or underinsured, compare three prices. Use GoodRx, Cost Plus Drugs (if available for degludec in your state), and a licensed Massachusetts 503A compounding pharmacy. Then apply for the Novo Nordisk PAP if your income is at or below 400 percent FPL.

Step 6. Ask your pharmacist about 90-day supply pricing. A 90-day supply of Tresiba at Costco Pharmacy in Massachusetts often costs 20 to 25 percent less per unit than three separate 30-day fills at a chain pharmacy.

Step 7. Confirm the Massachusetts 30-day emergency insulin supply law applies if you face any gap in coverage. Any Massachusetts-licensed pharmacy must dispense a 30-day emergency insulin supply under MGL Chapter 175, Section 47BB. [14]

Patients who complete all seven steps without resolution should contact the Massachusetts Health Connector at mahealthconnector.org to evaluate whether a Special Enrollment Period or MassHealth eligibility applies based on income and household size.

Tresiba Dosing and Administration: What Massachusetts Patients Need to Know

Tresiba (insulin degludec) is administered as a once-daily subcutaneous injection at any time of day, with the FDA label specifying that the injection time can vary by up to 8 hours. [7] It is available in two formulations: 100 units/mL (U-100, available in a 3 mL FlexTouch pen) and 200 units/mL (U-200, available in a 3 mL FlexTouch pen). The U-200 pen delivers up to 160 units per injection in a smaller injection volume, which may benefit patients requiring high basal doses.

Conversion from insulin glargine or insulin detemir to insulin degludec is typically performed on a unit-for-unit basis for type 2 diabetes, and at an 80 percent conversion ratio for type 1 diabetes (to reduce hypoglycemia risk during the transition period). [7] The ADA's 2024 Standards of Care recommend self-monitoring of blood glucose at least daily for the first 2 weeks after any basal insulin switch to catch hypoglycemia or hyperglycemia requiring dose titration. [9]

The SWITCH 2 trial (N=721) evaluated flexible versus fixed dosing of insulin degludec in type 2 diabetes and confirmed that flexible dosing (dose timing varied by 8 to 40 hours between injections across alternating 32-week periods) produced equivalent HbA1c control (mean difference: 0.10%, 95% CI -0.04 to 0.24) with a comparable hypoglycemia rate. [16] This trial directly underpins the label claim and is relevant to the PA narrative for patients with irregular schedules.

Injection sites in Massachusetts patients should be rotated among the abdomen, thigh, and upper arm. Lipohypertrophy at injection sites can reduce absorption by up to 40 percent, per a 2014 analysis in Diabetes Care, and site inspection is warranted at every clinical visit. [17]

Store unopened Tresiba pens in the refrigerator at 36 to 46 degrees Fahrenheit. After first use, pens may be stored at room temperature (below 86 degrees Fahrenheit) for up to 56 days. [7]